EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aging and immunotherapies: New horizons for the golden ages

Jamie A G Hamilton, Curtis J Henry

Aging and Cancer · 2020-12 · 1 (1-4) · 30-44

DOI: 10.1002/aac2.12014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging and Cancer, online erschienen am 30.09.2020. Verfasst von Jamie A G Hamilton und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIA NIH HHS, School of Medicine, Emory University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The life expectancy of the world's elderly population (65 and older) continues to reach new milestones with older individuals currently comprising greater than 8.5% (617 million) of the world's population. This percentage is predicted to approach 20% of the world's population by 2050 (representing 1.6 billion people). Despite this amazing feat, many healthcare systems are not equipped to handle the multitude of diseases that commonly manifest with age, including most types of cancers. As the world's aging population grows, cancer treatments continue to evolve. Immunotherapies are a new drug class that has revolutionized our ability to treat previously intractable cancers; however, their efficacy in patients with compromised immune systems remains unclear. In this review, we will discuss how aging‐associated losses in immune homeostasis impact the efficacy and safety of immunotherapy treatment in preclinical models of aging. We will also discuss how these findings translate to elderly patients receiving immunotherapy treatment for refractory and relapsed cancers, as well as, strategies that could be explored to improve the efficacy of immunotherapies in aged patients.

Schlagwörter

Stichwörter der Autor:innen

aginganti-inflammatory drugsclinical trialsimmunityimmunotherapiespreclinical models

Autor:innen und Institutionen

  • Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Förderung

  • NCI NIH HHS
  • NIA NIH HHS
  • School of Medicine, Emory University
  • National Institutes of Health
  • American Society of Hematology

Zitieren

APA

Hamilton, J. A. G., & Henry, C. J. (2020). Aging and immunotherapies: New horizons for the golden ages. Aging and Cancer, 1(1-4), 30-44. https://doi.org/10.1002/aac2.12014

Vancouver

Hamilton JAG, Henry CJ. Aging and immunotherapies: New horizons for the golden ages. Aging and Cancer. 2020;1(1-4):30-44. doi:10.1002/aac2.12014

BibTeX
@article{Hamilton2020,
  author = {Hamilton, Jamie A G and Henry, Curtis J},
  title = {Aging and immunotherapies: New horizons for the golden ages},
  journal = {Aging and Cancer},
  year = {2020},
  volume = {1},
  number = {1-4},
  pages = {30--44},
  doi = {10.1002/aac2.12014}
}
Kostenlos starten →